Chronic liver disease-related mortality in diabetes before and during the COVID-19 in the United States. Issue 1 (January 2023)

• Record Type: Journal Article
• Authors: Kim, Donghee; Alshuwaykh, Omar; Dennis, Brittany B.; Cholankeril, George; Knowles, Joshua W.; Ahmed, Aijaz
• Is Part Of: Digestive and liver disease. Volume 55:Issue 1(2023)
• Page Start: 3
• Page End: 10
• Publication Date: 2023-01
• Subjects: Nonalcoholic fatty liver disease -- Alcohol-related liver disease -- Cirrhosis -- Hepatitis; ALD alcohol-related liver disease -- CI confidence interval -- COVID-19 coronavirus disease 2019 -- HCV hepatitis C virus -- HCC hepatocellular carcinoma -- ICD-10 International Classification of Diseases Tenth Revision -- NAFLD nonalcoholic fatty liver disease -- NVSS National Vital Statistic System -- QPC quarterly percentage change; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; 616.33005
• DOI: 10.1016/j.dld.2022.09.006
• Languages: English
• ISSNs: 1590-8658

Abstract

Abstract: Background: Global pandemic of COVID-19 represents an unprecedented challenge. COVID-19 has predominantly targeted vulnerable populations with pre-existing chronic medical diseases, such as diabetes and chronic liver disease. Aims: We estimated chronic liver disease-related mortality trends among individuals with diabetes before and during the COVID-19 pandemic. Methods: Utilizing the US national mortality database and Census, we determined the quarterly age-standardized chronic liver disease-related mortality and quarterly percentage change (QPC) among individuals with diabetes. Results: The quarterly age-standardized mortality for chronic liver disease and/or cirrhosis among individuals with diabetes remained stable before the COVID-19 pandemic and sharply increased during the COIVD-19 pandemic at a QPC of 8.5%. The quarterly mortality from nonalcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD) increased markedly during the COVID-19 pandemic. Mortality for hepatitis C virus (HCV) infection declined with a quarterly rate of -3.3% before the COVID-19 pandemic and remained stable during the COVID-19 pandemic. While ALD- and HCV-related mortality was higher in men than in women, NAFLD-related mortality in women was higher than in men. Conclusions: The sharp increase in mortality for chronic liver disease and/or cirrhosis among individuals with diabetes during the COVID-19 pandemic was associated with increased mortality from NAFLD and ALD.